EGFR and non-small cell lung carcinoma: For example, erlotinib is a tyrosine kinase inhibitor (TKI) approved for first-line treatment of metastatic NSCLC in patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations33.